{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+Tablet&page=2",
    "query": {
      "intervention": "Naltrexone Tablet",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+Tablet&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T14:37:46.915Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02259179",
      "title": "Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)",
          "type": "DRUG"
        },
        {
          "name": "Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259179"
    },
    {
      "nct_id": "NCT01557257",
      "title": "Pharmacokinetics Study of ALO-02 and OxyContin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Management of Moderate to Severe Pain"
      ],
      "interventions": [
        {
          "name": "ALO-02",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone block",
          "type": "DRUG"
        },
        {
          "name": "OxyContin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 13,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01557257"
    },
    {
      "nct_id": "NCT02330419",
      "title": "Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Binge Drinking",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Medical Management (MM) counseling for alcohol use:",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Urinalysis for novel alcohol biochemical markers:",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Behavioral survey measurements:",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Dried Blood Spot (DSB) Testing for Phosphatidylethanol",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Ecological Momentary Assessment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "18 Years to 70 Years · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2015-04",
      "completion_date": "2021-01",
      "has_results": true,
      "last_update_posted_date": "2025-04-20",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02330419"
    },
    {
      "nct_id": "NCT01677065",
      "title": "A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxycodone controlled-release test formulation",
          "type": "DRUG"
        },
        {
          "name": "Immediate-release reference drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2012-09",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677065"
    },
    {
      "nct_id": "NCT04480554",
      "title": "Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid-use Disorder",
        "HIV-1-infection",
        "Immune Activation",
        "Inflammation",
        "Methadone",
        "Buprenorphine",
        "Naltrexone",
        "Antiretroviral Treatment"
      ],
      "interventions": [
        {
          "name": "Methadone",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "XR-Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 78,
      "start_date": "2023-01-30",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-07",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480554"
    },
    {
      "nct_id": "NCT01015066",
      "title": "Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opiate Addiction"
      ],
      "interventions": [
        {
          "name": "Buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "16 Years to 25 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-10",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01015066"
    },
    {
      "nct_id": "NCT04276259",
      "title": "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo",
          "type": "DRUG"
        },
        {
          "name": "IM Placebo",
          "type": "DRUG"
        },
        {
          "name": "Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Marta Peciña, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2020-10-19",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276259"
    },
    {
      "nct_id": "NCT02735603",
      "title": "Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Repolarization"
      ],
      "interventions": [
        {
          "name": "Naltrexone HCl/bupropion HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 84,
      "start_date": "2016-04",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-01",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735603"
    },
    {
      "nct_id": "NCT06140420",
      "title": "Naltrexone for Prolonged Grief Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Naltrexone HCl 50 MG Oral Tablet",
        "Placebo"
      ],
      "interventions": [
        {
          "name": "Naltrexone Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 7,
      "start_date": "2023-08-01",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06140420"
    },
    {
      "nct_id": "NCT04450316",
      "title": "Low-dose Naltrexone for Bladder Pain Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Pain Syndrome",
        "Interstitial Cystitis"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2020-10-08",
      "completion_date": "2022-06-04",
      "has_results": true,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-09-24T14:37:46.915Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04450316"
    }
  ]
}